ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Mallinckrodt Pays Big To Buy Questcor

by Rick Mullin
April 14, 2014 | APPEARED IN VOLUME 92, ISSUE 15

Mallinckrodt has agreed to purchase Questcor Pharmaceuticals for $5.6 billion. The deal will add Questcor’s only commercial product, H.P. Acthar Gel, to Mallinckrodt’s menu of specialty drugs. Acthar, approved in the U.S. for 19 indications, many associated with autoimmune and inflammatory diseases, generated sales of $761 million last year, a 50% increase over 2012. Questcor CEO Don M. Bailey has been credited with growing the company with the help of huge price increases for Acthar and the development of new applications. Mallinckrodt will also take on a small contract manufacturing business as part of the deal. Last year, Questcor acquired BioVectra, the Canadian producer of Acthar’s active ingredient, for $50 million.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment